UNSPSC 51192001: Allopurinol

This classification denotes a xanthine oxidase inhibitor and uricosuric agent with the molecular formula C5H4N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63CZ7GJN5I, chemically known as 1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidine-4-one but generally known as allopurinol, which bears US NIH Compound Identifier 2094. Allopurinol comes in various forms, including di-methyl, ribonucleoside, riboside, riboside 5-monophosphate, and sodium.

UNSPSC 51192001 Allopurinol is a Commodity code that nominally designates a single pharmaceutical product — allopurinol, a xanthine oxidase inhibitor used to treat gout and hyperuricemia — yet recent state and local procurement activity under this code shows minimal alignment with the drug itself. The three most recent opportunities posted under this code are an athletic training services RFP from the City of Tucson (due June 9, 2026), a medical aid supplies ITB from the City of Tampa Fire Rescue (posted April 24, 2026), and a Request for Information from the Texas Health and Human Services Commission regarding direct-to-manufacturer prescription programs (posted April 3, 2026). None of these solicitations explicitly reference allopurinol or single-drug procurement; instead, they address broader athletic training support, first-aid supply acquisition, and pharmacy benefit program strategy. The code shows little relevant recent activity for allopurinol specifically and appears to be a classification mismatch in the underlying procurement database.

Geographic activity is scattered across Arizona, Florida, and Texas, with no concentration evident in the sample. Issuing bodies include a city fire and police department (Tucson), a municipal fire rescue operation (Tampa), and a state health agency (Texas HHS). The Tampa opportunity included a $100,000 total budget and SLBE/U-WMBE set-asides with specific bid discounts. Given the disconnect between the commodity code and actual solicitation scope, firms pursuing pharmaceutical or gout-treatment drug sales should treat this code as a low-signal category and monitor downstream RFP releases from state Medicaid programs and health departments rather than rely on this code's historical tagging for pipeline development.